This NDC is on FDA's drug shortage list (posted May 3, 2018)
Product Information
LORAZEPAM 2 MG/ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $2.1170 per ML under NDC 65219036802. Its NADAC has been published 80 times since Feb 12, 2025.
FDA first approved this application on Nov 18, 2024. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
65219036802
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
8/19/2026
Active Ingredients
LORAZEPAMApproval Type
Generic (ANDA)
FDA Application
ANDA217598FDA Approved
11/18/2024
TE Code
AP
On Market Since
12/13/2024
Pharmacological Classes
Price Statistics
The NADAC for LORAZEPAM 2 MG/ML VIAL has been published 80 times since Feb 12, 2025, and over the history we have for it it has risen 94.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.1170 per ML |
|---|---|
| All-time high | $2.1170 (Aug 19, 2026) |
| All-time low | $1.0891 (Feb 12, 2025) |
| 52-week high | $2.1170 |
| 52-week low | $1.0891 |
| Median price | $1.0891 |
| Average price | $1.3101 |
| Largest weekly change | +54.6% (Mar 18, 2026) |
| Weeks tracked | 80 |
| Tracking since | Feb 12, 2025 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 68% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of LORAZEPAM 2 MG/ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for LORAZEPAM 2 MG/ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $2.1170 per ML (NDC 65219036802), effective Aug 19, 2026.
How has the price of LORAZEPAM 2 MG/ML VIAL changed over time?
Over the history we have for it, the NADAC for LORAZEPAM 2 MG/ML VIAL has risen 94.4%. It has been tracked across 80 weekly CMS publications since Feb 12, 2025.
What are the highest and lowest recorded NADAC prices for LORAZEPAM 2 MG/ML VIAL?
Since Feb 12, 2025, the NADAC for LORAZEPAM 2 MG/ML VIAL has ranged from a low of $1.0891 (Feb 12, 2025) to a high of $2.1170 (Aug 19, 2026), with a median of $1.0891 per ML.
Are there cheaper alternatives to LORAZEPAM 2 MG/ML VIAL?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, LORAZEPAM 20 MG/10 ML VIAL, is $0.6796 per ML — about 68% below LORAZEPAM 2 MG/ML VIAL.
Who manufactures LORAZEPAM 2 MG/ML VIAL?
LORAZEPAM 2 MG/ML VIAL (NDC 65219036802) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Is LORAZEPAM 2 MG/ML VIAL in shortage?
Yes — NDC 65219036802 is currently listed in FDA's drug shortage database (posted May 3, 2018).